Larocca A, Bonello F, Gaidano G, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 2021;137(22):3027-3036.

doi:10.1182/blood.2022018970

Skip Nav Destination

ERRATUM| February 16, 2023

Larocca A, Bonello F, Gaidano G, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 2021;137(22):3027-3036.

Blood (2023) 141 (7): 809.

https://doi.org/10.1182/blood.2022018970

Page 3031: In the last two rows of the leftmost column of Table 2, “ADL ≥4” should read “ADL ≤4” and “IADL ≥5” should read “IADL ≤5.” The errors have been corrected in the online version of the article.

2023

Full Text

Contents

Larocca A, Bonello F, Gaidano G, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 2021;137(22):3027-3036.

ASH Publications

American Society of Hematology

Contents

Cited By

Email alerts

Larocca A, Bonello F, Gaidano G, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 2021;137(22):3027-3036. Free

ASH Publications

American Society of Hematology

Contents

Related

Related

Cited By

Email alerts

This Feature Is Available To Subscribers Only

Larocca A, Bonello F, Gaidano G, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 2021;137(22):3027-3036.